Tag: clinical trials
-
Trial Shows Response to Antibody Treating Multiple Myeloma
27 August 2015. An early-stage clinical trial shows some patients receiving an engineered antibody to attack multiple myeloma cancer cells experienced at least a partial remission of their disease. Results of the study, led by oncologist Paul Richardson of Dana-Farber Cancer Institute and Harvard Medical School, appeared yesterday in New England Journal of Medicine. Multiple…
-
Alerts in Health Records Cut Delays in Cancer Diagnosis
25 August 2015. Medical researchers found electronic triggers that alert physicians when test results suggest a potential for cancer, reduce delays for patients needing follow-up care. The team led by Hardeep Singh, a professor at Baylor College of Medicine in Houston, published its findings yesterday in Journal of Clinical Oncology (paid subscription required). In addition…
-
Early Trial Results Targeting Cancer Mutations Promising
20 August 2015. A clinical trial testing the efficacy of a cancer drug to treat multiple types of cancer based on a common genomic mutation, showed a melanoma drug could treat at least a few other cancers. A team from the U.S. and Europe, led by researchers from Memorial Sloan Kettering Cancer Center in New…
-
Glucose Control Implant Bests Diabetes Drug in Trial
19 August 2015. A clinical trial shows an implanted system did a better job of lowering blood glucose levels in people with type 2 diabetes, than an approved glucose control drug. Intarcia Therapeutics in Boston, developer of the system code-named ITCA 650, released top-line results of the late-stage trial testing the device against the drug…
-
Cancer Precision Medicine Trial Underway
18 August 2015. A new clinical trial is enrolling participants that tests multiple types of therapies on a number of different cancers based on the genomic make-up of individual patients. The intermediate-stage trial is part of the National Cancer Institute’s Molecular Analysis for Therapy Choice, or NCI-MATCH program. NCI-MATCH seeks to determine if tumors with…
-
Blood Disease Biotech Gains $120 Million in IPO
12 August 2015. Global Blood Therapeutics, a biotechnology company developing treatments for blood-related disorders, is raising $120 million in its initial public stock offering. The company, in South San Francisco, California and trading on the Nasdaq exchange under the symbol GBT, issued 6 million shares priced at $20.00. Shares closed today trading at $43.50, more…
-
Trial Shows Fertility Treatment Boosts IVF Pregnancy Rate
11 August 2015. A clinical study of cellular treatments for women using in-vitro fertilization shows the treatments increased pregnancy rates compared to women receiving standard IVF alone. Findings from the study that tested treatments developed by IVF technology company OvaScience Inc. in Cambridge, Massachusetts are scheduled to be published on 25 August in the Journal…
-
Peanut Allergy Therapy Company Raises $160 Million in IPO
6 August 2015. Aimmune Therapeutics Inc., a developer of treatments for peanut and other food allergies, raised $160 million from its initial public stock offering, pricing its 10 million shares at $16.00. Shares in the Brisbane, California company trade on the Nasdaq exchange under the symbol AIMT. Shares closed today (6 August), priced at $24.10…
-
Trial Shows Weekly Growth Hormone Drug Effective, Safe
30 July 2015. Results of an intermediate-stage clinical trial show a drug candidate to treat growth hormone deficiency in children given once a week, works about as well as a current therapy requiring a daily injection. The results were released by Ascendis Pharma A/S, a specialty pharmaceutical company in Copenhagen, Denmark that conducted the trial.…
-
FDA Clears Trial of Fibrosis Drug for Muscular Dystrophy
24 July 2015. Biotechnology company Fibrogen Inc. says the U.S. Food and Drug Administration approved an application to test its fibrosis drug candidate in patients with Duchenne muscular dystrophy. The company says FDA’s approval was part of a new drug application for its candidate, code-named FG-3019, already in intermediate-stage clinical trials as a therapy for…